The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.
This activity features the perspectives of multiple sclerosis specialists on the rationale and clinical utility of recently approved and emerging disease-modifying therapies.
Review evidence-based therapeutic options for the management of motor fluctuations and dyskinesia in PD and discuss new and emerging levodopa and non-levodopa-based therapies.
